Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions


Por: Porras, VRD, Pardo, JC, Etxaniz, O and Font, A

Publicada: 1 oct 2022 Ahead of Print: 1 ago 2022
Resumen:
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard treatment for patients with muscle-invasive bladder cancer (MIBC). However, the implementation of NAC is lower than desirable mainly due to its limited impact on overall survival, patients' comorbidities and the lack of predictive biomarkers to select those patients most likely to benefit from NAC. In the last decade, improved molecular MIBC characterisation, the identification of potential predictive and prognostic biomarkers as well as the incorporation of new effective therapies with a better toxicity profile, such as immunotherapy, has changed the treatment paradigm for MIBC. Therefore, the main goal for the near future is to introduce these clinical and translational advances into routine clinical practice to personalise treatment for each patient and increase the opportunity to implement bladder preservation strategies. The present review focuses on the current status of NAC in MIBC, unsolved questions and future therapeutic approaches.

Filiaciones:
:
 Catalan Inst Oncol, Badalona Appl Res Grp Oncol B ARGO, Badalona 08916, Spain

 Germans Trias & Pujol Res Inst IGTP, Badalona 08916, Spain

:
 Catalan Inst Oncol, Badalona Appl Res Grp Oncol B ARGO, Badalona 08916, Spain

 Germans Trias & Pujol Res Inst IGTP, Badalona 08916, Spain

 Catalan Inst Oncol, Med Oncol Dept, Ctra Can Ruti Cami Escoles S-N, Badalona 08916, Spain

:
 Catalan Inst Oncol, Badalona Appl Res Grp Oncol B ARGO, Badalona 08916, Spain

 Germans Trias & Pujol Res Inst IGTP, Badalona 08916, Spain

 Catalan Inst Oncol, Med Oncol Dept, Ctra Can Ruti Cami Escoles S-N, Badalona 08916, Spain

:
 Catalan Inst Oncol, Badalona Appl Res Grp Oncol B ARGO, Badalona 08916, Spain

 Germans Trias & Pujol Res Inst IGTP, Badalona 08916, Spain

 Catalan Inst Oncol, Med Oncol Dept, Ctra Can Ruti Cami Escoles S-N, Badalona 08916, Spain
ISSN: 10408428





CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Editorial
Elsevier BV, STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA, Países Bajos
Tipo de documento: Review
Volumen: 178 Número:
Páginas:
WOS Id: 000848052800001
ID de PubMed: 35988856

MÉTRICAS